Literature DB >> 34872585

First patient in the Iranian Registry with novel DOCK2 gene mutation, presenting with skeletal tuberculosis, and review of literature.

Niusha Sharifinejad1, Homa Sadri2,3, Arash Kalantari4, Samaneh Delavari5, Amirhosein Noohi6, Yasaman Aminpour6, Araz Sabzevari7, Gholamreza Azizi8,9.   

Abstract

BACKGROUND: Dedicator of cytokinesis 2 (DOCK2) deficiency is an inborn error of immunity characterized by cellular and humoral immunological abnormalities leading to early-onset infections. CASE
PRESENTATION: We reported a novel case of a 27 months old girl presenting with recurrent pneumonia and a history of skeletal tuberculosis at the age of 19-month-old. Her immunological workup revealed persistent lymphopenia and low CD4 + T cell count along with elevated levels of CD19 +, CD20 +, CD16 +, and CD56 + cells. Furthermore, she had a high level of immunoglobulin (Ig) E and a slightly reduced IgM level with a non-protective antibody titer against diphtheria. The whole-exome sequencing (WES) analysis identified a homozygous frameshift deletion mutation (c.1512delG, p.I505Sfs*28) in exon 16 of the DOCK2 gene. We also conducted electronic searches in PubMed, Web of Science, and Scopus databases and reviewed the articles reporting patients with DOCK2 deficiency. The literature search yielded 14 DOCK2-deficient patients suffering from both cellular and humoral immune defects leading to early-onset infections, particularly human herpesvirus (HHV) infection.
CONCLUSION: DOCK2 deficiency should be considered in the context of severe or unusual early-onset infections, especially HHV infections, in a patient with a probable clinical diagnosis of combined immunodeficiency. We also recommended that DOCK2-deficient patients might benefit from T-cell receptor excision circle (TREC) assay as part of the routine newborn screening program.
© 2021. The Author(s).

Entities:  

Keywords:  CID; Combined immunodeficiency; DOCK2 deficiency; Dedicator of cytokinesis 2 deficiency; Primary Immunodeficiency

Year:  2021        PMID: 34872585      PMCID: PMC8647063          DOI: 10.1186/s13223-021-00631-5

Source DB:  PubMed          Journal:  Allergy Asthma Clin Immunol        ISSN: 1710-1484            Impact factor:   3.406


Introduction

Dedicator of cytokinesis 2 (DOCK2) is a subfamily of guanine exchange factors required for the activation of intercellular GTPases and subsequent release of adenosine triphosphate (ATP) in response to various stimuli [1]. DOCK2, specifically, expresses on immune cells and promotes the activation and migration of B cell and T cell lymphocytes. Besides, it promotes the cytotoxicity and degranulation of natural killer (NK) cells and the thymic development of NKT cells. Additionally, DOCK2 is reported to mediate the production of reactive oxygen species (ROS) and chemotaxis in neutrophils [2]. Biallelic loss-of-function mutations in the DOCK2 gene are associated with clinical features of combined immunodeficiency (CID) according to the primary immunodeficiency (PID) treatment consortium (PIDTC) [3, 4]. Different DOCK2 mutations resulted in absent or significantly reduced levels of DOCK2 protein expression that precede a chain of immunological defects including CD4 + and CD8 + T cells lymphopenia with reduced T cell receptor excision circles (TRECs), diminished phytohemagglutinin (PHA)-induced T cell proliferation, impaired NK cell function, decrease B cell counts, and defective antibody responses in DOCK2-deficient patients [3]. These immunological disturbances commence early-onset and severe infections in patients harboring DOCK2 mutations that often lead them to death [5]. Hematopoietic stem cell transplantation (HSCT) is currently the only curative option for DOCK2-deficient patients [3]. Here, we report a 27 months old girl who presented with severe infection and carried a novel homozygous frameshift deletion c.1512delG (p.I505Sfs*28) mutation at exon 16 of the DOCK2 gene. We have also reviewed the data of previously reported patients with DOCK2 deficiency.

Patient and methods

The demographic data, medical history, and physical examination of the patient were obtained through direct interviews and examining the patient’s clinical record in the Imam-Ali Karaj Hospital affiliated to Alborz University of Medical Sciences, using national consensus on diagnosis and management guidelines for PID [6]. Written informed consent was obtained from the parents, following the principles of the ethics committee of the Alborz University of Medical Sciences. Basic hematological, biochemistry, and immunological investigations including enumeration of lymphocyte subsets: T- and B-cells subsets (assessed using flow cytometry analysis), serum levels of immunoglobulins, complements, and antibodies (assessed using nephelometry and enzyme-linked immunosorbent assay). Secondary causes of lymphopenia were excluded by history taking and laboratory tests, and no sign of drug or disease-related causes was detected. Clinical diagnosis of CID has been established according to the criteria of the European Society for Immunodeficiencies [7]. The whole peripheral blood sample was used to extract genomic DNA. The whole-exome sequencing (WES) and the confirmatory Sanger sequencing were performed according to a previously published pipeline [8, 9]. The literature searches for reported DOCK2-deficient patients were conducted in PubMed, Web of Science, and Scopus, using the following keywords: DOCK2 deficiency and Dedicator of cytokinesis 2 deficiency. The articles were primarily screened based on the title and abstract to exclude immaterial studies and then the full-text manuscripts of the included studies were assessed to determine their eligibility criteria (written in English, conducted on human subjects, reporting at least one patient with DOCK2 deficiency diagnosis). The descriptive section is subsequently developed based on this information.

Case presentation

The patient was a 26-month-old girl born to first-degree consanguineous Iranian/Turkish parents. She was born at term gestational age with 3200 g weight and underwent routine age-matched vaccination in Iran including BCG vaccine at birth, Polio, Hepatitis B, Diphtheria, Tetanus, Haemophilus Influenza type B, Pertussis, and MMR (mumps, measles, rubella) until 18 months old, without remarkable adverse event. She had an older sister who died at the age of 1.5 years with diarrhea as the main clinical symptom (Fig. 1). At 18 months of age, she was hospitalized due to pneumonia and otitis media with perforated tympanic membrane and pus discharge. By that time, her growth and developmental state were age-appropriate and she had not experienced prior hospitalization or considerable infection. Only a few days after her discharge, she developed right thigh swelling, tenderness, and heat, unable of weight-bearing. Therefore, she was admitted once more for suspected acute osteomyelitis. The right femur X-ray showed evidence of osteomyelitis (Fig. 2). Later, she underwent an open biopsy and the mycobacterium tuberculosis (MTB) DNA complex was detected in the tissue sections obtained from her right femur, using Xpert MTB/RIF Ultra assay which is a rapid and accurate diagnostic tool, especially in extra-pulmonary tuberculosis [10]. Plus, the smear of skeletal canal fluid specimen confirmed the presence of many acid-fast positive bacilli. Meantime, chest radiographs of the patient and her parents were evaluated and although her parents had no lesion compatible with pulmonary TB, the patient’s X-ray showed round density in the middle lobe of the right lung. They had no contact history of TB. She was treated with Isoniazid, Rifampin, Ethambutol, Pyrazinamide, and vitamin B6 for 9 months with the diagnosis of skeletal tuberculosis. The patient’s unusual infection with an uncommon microorganism prompted an immunological workup to detect the possible underlying immunodeficiency (Table 1). Based on her clinical and initial laboratory data, she was recommended for a thorough evaluation, but her parents refused further investigation.
Fig. 1

The family pedigree of the patient with DOCK2 deficiency

Fig. 2

The X-ray of the patient shows signs of periosteal reaction in the diaphysis (red arrow) and a lucent area with sclerotic borders in the metaphysis of right femur (yellow arrow)

Table 1

Immunologic work-up of the DOCK2 deficient-patient

Parameters19 months old26 months oldNormal ranges
WBC × 103 (cell/µL)25.56.75.5–15.5
Lymphocytes (cell/µL )11,70016413873–6141
Hemmoglobin (g/dL)9.59.810.9–15
CD3 + T cells (cell/µL)647017091578–3707
CD4 + T cells (cell/µL)32234870–2144
CD8 + T cells (cell/µL)2697581472–1107
CD4/CD8 Ratio0.160.0580.9–3.7
CD19 + (cell/µL)25971900434–1274
CD20 + (cell/µL)ND1900124–1665
CD16 + (cell/µL)1111117878–703
CD56 + (cell/µL)174387445–555
CD16 + 56 (cell/µL)760380155–565
IgG (mg/dL)ND511424–1051
IgM (mg/dL)794148–168
IgA (mg/dL)7285.114–123
IgE (IU/mL)471400 < 100
C3 (mg/mL)113ND84–174
C4 (mg/mL)27ND12–40
CH50 (IU/mL) > 9011670–150
MFI/PMA ox-DHR (%)40.2%ND > 30%
HIV 1,2 antigen/ antibody (S/CO)ND0.03 < 0.9
Anti-tetanus antibody (IU/mL)ND0.19 > 0.1
Anti-diphtheria antibody (IU/mL)ND0.03 > 0.1

ND not determined, Ig immunoglobulin, WBC white blood cell, C3 complement component 3, C4 complement component 4, CH50 total hemolytic complement, MFI/PMA ox-DHR mean fluorescence intensity/phorbol myristate acetate oxy dihydrorhodamine, HIV 1,2 human immunodeficiency virus 1,2

Abnormal value are indicates in bold

The family pedigree of the patient with DOCK2 deficiency The X-ray of the patient shows signs of periosteal reaction in the diaphysis (red arrow) and a lucent area with sclerotic borders in the metaphysis of right femur (yellow arrow) Immunologic work-up of the DOCK2 deficient-patient ND not determined, Ig immunoglobulin, WBC white blood cell, C3 complement component 3, C4 complement component 4, CH50 total hemolytic complement, MFI/PMA ox-DHR mean fluorescence intensity/phorbol myristate acetate oxy dihydrorhodamine, HIV 1,2 human immunodeficiency virus 1,2 Abnormal value are indicates in bold A few months later, she was referred to our hospital with fever, cough, and shortness of breath and eventually admitted to the pediatric intensive care unit (PICU) due to severe tachypnea and respiratory distress with the diagnosis of severe pneumonia. During her admission, she received empirical broad-spectrum antibiotics with full coverage of bacteria, viruses, and fungi. Nonetheless, no pathogenic microorganism was isolated from the patient and despite receiving the standard treatment, her respiratory condition worsened and she got intubated. Her inadequate response to standard treatment led to afresh immunological workup. The laboratory results revealed anemia, lymphopenia along with decreased CD4 + count, and CD4/CD8 ratio similar to her previous records (Table 1). She also had increased CD19 +, CD20 +, CD16 +, and CD56 + cell counts. Her anti-diphtheria antibody titer was beneath the protective level despite the age-matched vaccination. She had hyper immunoglobulin (Ig) E and a slightly reduced IgM level (Table 1). Based on her results, a probable CID was suspected and genetic analysis was performed on whole blood samples using WES. The WES analysis and Sanger sequencing revealed a homozygous frameshift deletion mutation c.1512delG (p.I505Sfs*28) at exon 16 in the DOCK2 gene loci. Meanwhile, her serum creatinine and urea level increased significantly (2.5 and 248.5 mg/dL, respectively) and she underwent peritoneal dialysis. During her admission, she suffered from pneumothorax and few episodes of seizure as well. Unfortunately, she was deceased at the age of 27-month-old due to multi-organ failure.

Review of literature

So far, 14 DOCK2-deficient cases (8 males, 4 females, and 2 unknown gender) were reported in six different studies from various ethnicities. Consanguinity and positive family history of immunodeficiency were reported in 81.8% (9 out of 11 cases) and 44.4% (4 out of 9 cases) of patients, respectively. All patients with available data developed infection as their first manifestation of immunodeficiency within the first months of birth. Half of the patients (6 of 12) also presented with infections caused by different members of the human herpesvirus family (HHV) including HHV6, varicella, and Cytomegalovirus (CMV). Fifty-seven percentage (8 of 12) of patients had lymphopenia. The major immunological abnormalities in lymphocyte subsets were; low CD3 + in 64.2% (9 of 14), low CD4 + in 78.6% (11 of 14), low CD8 + in 50% (7 of 14), low CD19 + in 50% (7 of 14), and low NK counts in 50% (7 of 14). IgM levels were decreased in 7 cases (50%) and increased in 3 cases (21.4%). Elevated/or reduced IgA levels were present in 3 cases (21.4%). IgG levels were mainly normal among the patients (78.6%). Nine patients showed decreased T-cell response to PHA, and of those, six patients had the SCID response range [11]. All of the cases that were tested for TREC (4 cases) had decreased TREC levels. Poor response to vaccination and absent antibody responses to infectious agents were also reported in some cases. HSCT was performed as the main treatment in 77.8% (7 of 9) of patients resulting in achieved engraftment in 5 (71.4%) patients. Further information is available in Table 2.
Table 2

An overview of the clinical and immunological findings of reported cases with DOCK2 deficiency

NoSexEthnicityCONFHAOO (m)AF-InfInfectionOther manifestationsImmunological abnormalityDOCK2 mutation/proteinTreatmentOutcomeRefs.
1MLebanese+33RSV bronchiolitis, recurrent pneumonia,Lymphopenia, decreased CD3 +, CD4 + , and CD8 +, decreased IgM level, decreased T-cell response to PHAp.Y1242Yfs*33HSCT (myeloablative)Alive[3]
2FFinnish < 24 < 24Recurrent otitis media, pneumonia, diarrhea, Varicella, M. avium, and HHV-6 infectionThree episodes of thrombocytopeniaLymphopenia, decreased CD3 +, CD4 +, CD8 +, and CD19 + cells decreased IgM, increased IgE and IgA, decreased T-cell response to PHA, decreased TREC, Non-protective against tetanus toxoid, PRP, Streptococcus pneumoniaep.R1104W, p.Q1324*HSCT (reduced-intensity)Alive[3]
3MTurkish +  + 33Recurrent respiratory tract infections, meningoencephalitis, severe varicella infection, mumps,Lymphopenia, decreased CD3 +, CD4 +, and CD8 +, decreased T-cell response to PHA, No response to VZVp.R751SNDDead[3]
4MTurkish +  < 3 < 3Chronic diarrhea, oral moniliasis, recurrent pneumonia with parainfluenza virus type 3 and adenovirus, CMV infection, Klebsiella pneumoniae sepsisFTT, nodular erythematous lesion at the site of bacille Calmette–Guerin vaccination, hepatomegaly with persistently elevated aminotransferase levels, colitisLymphopenia, decreased CD3 +, CD4 +, CD19 +, and NK, decreased IgM level, increased IgA, decreased T-cell response to PHA, decreased TREC, Response to HBV not detectablep.F744Cfs*27NDDead[3]
5MHispanic44Interstitial pneumoniaRectal fistulaDecreased CD3 +, CD4 +, CD8 +, increased NK cells, increased IgM and IgE, decreased T-cell response to PHA, Response to KLH not detectablep.P1476L, p.M120Mfs*22High-dose trimethoprim–sulfamethoxazole, HSCT (myeloablative)Alive[3]
6FIranian + 22Septicemia, diarrhea, CMV infectionSeizuresThrombocytopenia, lymphocytopenia, reduced CD4 +, CD19 +, NK cells, elevated IgM, decreased TREC, T cell response to PHA and T cell response to BCGc.C3310T, p.R1104WAntibiotics, antiviral treatment, and IVIGDead[5]
7MMoroccan +  + 00E.coli pyelonephritisUlcerative perianal dermatitis, Omenn syndrome, nephrotic syndrome, ARDS, capillary leak syndromeLymphopenia, decreasedCD3 +, CD4 +, CD8 +, CD19 +, and NK, decreased IgM and IgA, Absent TREC, absent T cell response to PHAc.2704-2 A > CHSCT, etanercept, tocilizumab, and high-dose steroidsDead[12]
8MMoroccan +  + 2.5NDSepsis, Respiratory, distress, Hepatitis, CMV, Enterovirus, Rhinovirus, and Pneumocystis jiroveci infectionsARDS, Bloody diarrhea LivedoLymphopenia, decreased CD3 +, CD4 +, CD8 +, absent T cell response to PHAc.2704-2 A > CHSCTDead[12]
9FMoroccan +  + 0NDInfluenza A and Rhinovirus infectionBloody diarrheaLymphopenia, decreased CD3 +, CD4 +, CD8 +, CD19 +, and NKc.2704-2 A > CHSCT (without conditioning)Alive[12]
10FND + ND0.50.5Recurrent sinopulmonary infections, CMV viremiaChronic diarrheaDecreased CD4 + and IgG level, increased IgM, decreased T cell response to PHA and BCGc.del 902-1078IVIG, ganciclovir, HSCT (myeloablative)Alive[13]
11MND + ND55Recurrent pneumonias, oral candidiasis, sepsisChronic diarrheaDecreased CD4 + and CD19 +, panhypogammaglobulinemiaPhe848fsIVIG, prophylactic antibioticsDead[13]
12MIndianNDNDNDNDOtitis media, recurrent pneumonia with atypical mycobacterial and influenza InfectionsDecreased CD3 +, decreased IgA and IgM levelc.3430C > T, p.Arg1144TerNDND[16]
13NDChineseNDNDNDNDNDNDLeukopenia, increased CD3 +, CD4 +, and CD8 +, decreased CD19 + and NK, decreased IgM and IgGc.5335A > T, c.2423 T > CNDND[14]
14NDChineseNDNDNDNDNDNDIncreased CD19 +, decreased NK, increased IgA and IgGc.743A > G, c.5048C > TNDND[14]
15FIranian/Turkish +  + 1818Pneumonia, otitis media, skeletal tuberculosisRenal failure, pneumothorax, and seizureLymphopenia, decreased CD4 +, increased CD19 +, CD20 +,CD16 +, and CD56 +, decreased IgM, increased IgE, Non-protective against diphtheria toxoidc.1512delG: p.I505Sfs*28Antibiotics, antiviral, antifungal, and anti-tuberculosis drugs, peritoneal dialysisDeadOur case

No. number, CON. consanguinity, FH family history, AOO age of onset, m months, AF-Inf age of first infection, Ref. reference, ND not determined, RSV respiratory syncytial virus, HSCT hematopoietic stem-cell transplantation, CMV cytomegalovirus, HHV human herpes virus, Ig immunoglobulin, NK natural killer, IVIG intravenous immune globulin, TRECs T cell receptor excision circles, PHA phytohemagglutinin, ARDS acute respiratory distress syndrome, BCG Bacillus Calmette–Guérin, FTT failure to thrive, VZV Varicella-zoster virus, HBV hepatitis B virus, KLH keyhole limpet hemocyanin, PRP polyribosylribitol phosphate

An overview of the clinical and immunological findings of reported cases with DOCK2 deficiency No. number, CON. consanguinity, FH family history, AOO age of onset, m months, AF-Inf age of first infection, Ref. reference, ND not determined, RSV respiratory syncytial virus, HSCT hematopoietic stem-cell transplantation, CMV cytomegalovirus, HHV human herpes virus, Ig immunoglobulin, NK natural killer, IVIG intravenous immune globulin, TRECs T cell receptor excision circles, PHA phytohemagglutinin, ARDS acute respiratory distress syndrome, BCG Bacillus Calmette–Guérin, FTT failure to thrive, VZV Varicella-zoster virus, HBV hepatitis B virus, KLH keyhole limpet hemocyanin, PRP polyribosylribitol phosphate

Discussion

In this study, we reported a 27-month-old girl presenting with recurrent, severe, early-onset infections. The laboratory data revealed defective cellular and humoral immune systems and the patient was found to harbor a novel homozygous frameshift deletion mutation c.1512delG (p.I505Sfs*28) at exon16 of the DOCK2 gene. Similar to the immunological results of patients reported by Dobbs et al. and Moens et al. [3, 12], our patient had lymphopenia along with decreased CD4 + cell count and IgM level. However, in contrast to our patient’s results, these studies also described decreased CD3 + and CD8 + cell counts as well as defective antibody responses in patients with DOCK2 deficiency [3, 12]. Of note, the persistent lymphopenia observed in DOCK2-deficient patients could be due to the recurrent infections that occurred in these cases, which is more prominent in our patient who manifested with skeletal tuberculosis, an unusual infection that has not been previously reported. In contrast, the index patient in Moens et al.’s study was reported to have lymphopenia and reduced TREC level at birth and prior to infection [12]. Therefore, more studies are required to elucidate whether lymphopenia is inherent to DOCK2 deficiency. Additionally, our patients received age-matched vaccination including BCG, and did not represent any adverse reaction. Dobbs et al. were the first study that described DOCK2-deficient patients with three out of the five patients developing HHV infections [3]. Later, Alizadeh et al. proposed a hypothesis based on the results of their patient and Dobbs et al.’s, indicating a probable association between DOCK2 deficiency and susceptibility to various HHV infections [5] which was subsequently strengthened by the results of other studies [12, 13]. Even so, no sign of HHV-related infections was detected in our case. We also observed elevated IgE level in our patient that was only expressed previously by Dobbs K et al. [3]. Unlike our patient’s laboratory data, most of the DOCK2-deficient patients had decreased CD19 + cell counts. However, a recent study of a Chinese patient also reported an increased CD19 + cell count [14]. We found a total of 14 DOCK2-deficient patients skewing toward male patients (57.1%) in the published literature. Positive family history of immunodeficiency and parental consanguinity were important factors in the patients that are affirmative according to the autosomal recessive inheritance of DOCK2 deficiency [3]. The prevalent immunological abnormalities among reported patients were as follows: low CD3 +, low CD4 +, low CD8 +, low CD19 +, and low NK cell counts along with reduced IgM and normal IgG levels. Decreased T-cell responses to PHA were also present in the range defined for SCID [11]. Given all cases with available data had low TREC levels and the arguable evidence of lymphopenia adherence to this disease, DOCK2 deficiency could be recognizable through newborn SCID screening programs [15]. Unfortunately, we were not able to determine the T-cell response to PHA and TREC levels of our patient due to her rather rapid clinical deterioration and death.

Conclusion

In summary, DOCK2 deficiency should be contemplated in the context of severe or unusual early-onset infections, especially HHV infections, accompanied by laboratory data indicating both cellular and humoral defects. Decreased CD4 + T cell count was the most prevalent immunological abnormality detected in these patients. The role of the newborn TREC screening program in detecting suspected patients with DOCK2 deficiency needs to be clarified in the upcoming studies. Further investigations are required to discover the possible associations between this genetic defect and the laboratory/or clinical features of the disease.
  14 in total

1.  DOCK2 Deficiency in a Patient with Hyper IgM Phenotype.

Authors:  Zahra Alizadeh; Marzieh Mazinani; Leila Shakerian; Mohammad Nabavi; Mohammad R Fazlollahi
Journal:  J Clin Immunol       Date:  2017-12-04       Impact factor: 8.317

2.  DOCK2 couples with LEF-1 to regulate B cell metabolism and memory response.

Authors:  Lu Yang; Yukai Jing; Wenjie Wang; Wenjing Ying; Li Lin; Jiang Chang; Li Luo; Danqing Kang; Panpan Jiang; Ju Liu; Qiuyue Chen; Heather Miller; Andrés A Herrada; Masato Kubo; Jinqiao Sun; Chaohong Liu
Journal:  Biochem Biophys Res Commun       Date:  2020-06-29       Impact factor: 3.575

3.  Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins.

Authors:  H Nishihara; S Kobayashi; Y Hashimoto; F Ohba; N Mochizuki; T Kurata; K Nagashima; M Matsuda
Journal:  Biochim Biophys Acta       Date:  1999-11-11

Review 4.  Dock2 in the development of inflammation and cancer.

Authors:  Yayun Chen; Fan Meng; Bingyu Wang; Liangmei He; Yangbin Liu; Zhiping Liu
Journal:  Eur J Immunol       Date:  2018-04-11       Impact factor: 5.532

5.  Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience.

Authors:  William T Shearer; Elizabeth Dunn; Luigi D Notarangelo; Christopher C Dvorak; Jennifer M Puck; Brent R Logan; Linda M Griffith; Donald B Kohn; Richard J O'Reilly; Thomas A Fleisher; Sung-Yun Pai; Caridad A Martinez; Rebecca H Buckley; Morton J Cowan
Journal:  J Allergy Clin Immunol       Date:  2013-11-28       Impact factor: 10.793

Review 6.  Next Generation Sequencing Data Analysis in Primary Immunodeficiency Disorders - Future Directions.

Authors:  Mingyan Fang; Hassan Abolhassani; Che Kang Lim; Jianguo Zhang; Lennart Hammarström
Journal:  J Clin Immunol       Date:  2016-03-18       Impact factor: 8.317

7.  Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections.

Authors:  Kerry Dobbs; Cecilia Domínguez Conde; Shen-Ying Zhang; Silvia Parolini; Magali Audry; Janet Chou; Emma Haapaniemi; Sevgi Keles; Ivan Bilic; Satoshi Okada; Michel J Massaad; Samuli Rounioja; Adel M Alwahadneh; Nina K Serwas; Kelly Capuder; Ergin Çiftçi; Kerstin Felgentreff; Toshiro K Ohsumi; Vincent Pedergnana; Bertrand Boisson; Şule Haskoloğlu; Arzu Ensari; Michael Schuster; Alessandro Moretta; Yuval Itan; Ornella Patrizi; Flore Rozenberg; Pierre Lebon; Janna Saarela; Mikael Knip; Slavé Petrovski; David B Goldstein; Roberta E Parrott; Berna Savas; Axel Schambach; Giovanna Tabellini; Christoph Bock; Talal A Chatila; Anne Marie Comeau; Raif S Geha; Laurent Abel; Rebecca H Buckley; Aydan İkincioğulları; Waleed Al-Herz; Merja Helminen; Figen Doğu; Jean-Laurent Casanova; Kaan Boztuğ; Luigi D Notarangelo
Journal:  N Engl J Med       Date:  2015-06-18       Impact factor: 91.245

8.  Primary Immunodeficiencies in India: Molecular Diagnosis and the Role of Next-Generation Sequencing.

Authors:  Arun Kumar Arunachalam; Madhavi Maddali; Fouzia N Aboobacker; Anu Korula; Biju George; Vikram Mathews; Eunice Sindhuvi Edison
Journal:  J Clin Immunol       Date:  2020-11-23       Impact factor: 8.317

9.  Xpert MTB/RIF ultra for rapid diagnosis of extrapulmonary tuberculosis in a high-income low-tuberculosis prevalence setting.

Authors:  Ida Marie Hoel; Heidi Syre; Ingerid Skarstein; Tehmina Mustafa
Journal:  Sci Rep       Date:  2020-08-18       Impact factor: 4.379

Review 10.  Universal Newborn Screening for Severe Combined Immunodeficiency (SCID).

Authors:  Mirjam van der Burg; Nizar Mahlaoui; Hubert Bobby Gaspar; Sung-Yun Pai
Journal:  Front Pediatr       Date:  2019-09-18       Impact factor: 3.418

View more
  1 in total

Review 1.  Insights from DOCK2 in cell function and pathophysiology.

Authors:  Lulin Ji; Shuquan Xu; Haiqing Luo; Fanwei Zeng
Journal:  Front Mol Biosci       Date:  2022-09-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.